PDCD1 and cancer: As T-cell exhaustion correlates with a poor outcome in cancer patients, there has been a considerable interest in targeting T-cell exhaustion to enhance immune responses to cancer cells.13 Targeting T-cell exhaustion using PD-1 blocking antibodies is a proof of concept that blockade of co-inhibitory receptors can restore a functional T-cell response.